We are live on
!
Find out more
IIM
INTECH Investment Management Portfolio holdings
AUM
$10.2B
1-Year Est. Return
28.14%
This Fund
S&P 500
This Quarter
Est. Return
+4.47%
1 Year Est. Return
+28.14%
3 Year Est. Return
+94.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$10.3B
AUM Growth
+$1.38B
(+15%)
Cap. Flow
+$1.28B
Cap. Flow
% of AUM
12.43%
Top 10 Holdings %
Top 10 Hldgs %
25.81%
Holding
2,444
New
431
Increased
1,575
Reduced
361
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$48.2M |
| 2 |
Cintas
CTAS
|
+$42.2M |
| 3 |
Centene
CNC
|
+$41.9M |
| 4 |
UnitedHealth
UNH
|
+$41.6M |
| 5 |
Wells Fargo
WFC
|
+$39.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$109M |
| 2 |
Amazon
AMZN
|
+$77.8M |
| 3 |
Vanguard Russell 2000 ETF
VTWO
|
+$64.9M |
| 4 |
Microsoft
MSFT
|
+$44.1M |
| 5 |
Deckers Outdoor
DECK
|
+$42.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.23% |
| 2 | Financials | 13.8% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 10.79% |
| 5 | Consumer Discretionary | 10.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Commercial Vehicle Group
CVGI
$147M
| $38.5K | ﹤0.01% |
+15,508
| New | +$41.4K |
|
2352
Coherus Oncology
CHRS
$196M
| $38.1K | ﹤0.01% |
+27,600
| New | +$31K |
|
2353
LiveOne
LVO
$58.2M
| $37.6K | ﹤0.01% |
+2,556
| New | +$22.3K |
|
2354
1stdibs.com
DIBS
$171M
| $35.9K | ﹤0.01% |
+10,143
| New | +$41K |
|
2355
Harvard Bioscience
HBIO
$29.2M
| $35.4K | ﹤0.01% |
+1,680
| New | +$38.6K |
|
2356
Nautilus Biotechnolgy
NAUT
$115M
| $35.2K | ﹤0.01% |
+20,951
| New | +$50.1K |
|
2357
Pyxis Oncology
PYXS
$236M
| $35.1K | ﹤0.01% |
22,491
+7,594
| +51% | +$21.9K |
|
2358
Holley
HLLY
$384M
| $34.4K | ﹤0.01% |
11,375
-2,598
| -19% | -$7.28K |
|
2359
Information Services Group
III
$251M
| $34.2K | ﹤0.01% |
+10,242
| New | +$34.2K |
|
2360
Fractyl Health
GUTS
$111M
| $33.8K | ﹤0.01% |
+16,414
| New | +$38.2K |
|
2361
Acumen Pharmaceuticals
ABOS
$176M
| $32.4K | ﹤0.01% |
+18,847
| New | +$45.4K |
|
|
AKYA
2362
DELISTED
Akoya BioSciences
AKYA
| $27K | ﹤0.01% |
+11,780
| New | +$31.2K |
|
|
HLVX
2363
DELISTED
HilleVax
HLVX
| $26.2K | ﹤0.01% |
+12,647
| New | +$23.7K |
|
2364
FibroBiologics
FBLG
$6.5M
| $25.3K | ﹤0.01% |
+633
| New | +$34K |
|
|
GBIO
2365
DELISTED
Generation Bio
GBIO
| $24.7K | ﹤0.01% |
+2,334
| New | +$41.6K |
|
|
CLYM
2366
Climb Bio
CLYM
$804M
| $24.7K | ﹤0.01% |
+13,701
| New | +$49.6K |
|
2367
908 Devices
MASS
$364M
| $23.9K | ﹤0.01% |
+10,885
| New | +$31.2K |
|
|
RAPT
2368
DELISTED
RAPT Therapeutics
RAPT
| $23.3K | ﹤0.01% |
+1,844
| New | +$23.4K |
|
2369
Century Therapeutics
IPSC
$361M
| $23.1K | ﹤0.01% |
+22,892
| New | +$31.2K |
|
2370
Ovid Therapeutics
OVID
$491M
| $22.2K | ﹤0.01% |
+23,724
| New | +$26.5K |
|
2371
ALX Oncology
ALXO
$290M
| $22K | ﹤0.01% |
+13,198
| New | +$20.3K |
|
2372
Werewolf Therapeutics
HOWL
$19.3M
| $22K | ﹤0.01% |
+14,866
| New | +$30.3K |
|
2373
Inovio Pharmaceuticals
INO
$69M
| $22K | ﹤0.01% |
+12,007
| New | +$53.1K |
|
2374
Shattuck Labs
STTK
$694M
| $21.8K | ﹤0.01% |
+18,012
| New | +$22.3K |
|
2375
Actinium Pharmaceuticals
ATNM
$25M
| $17.9K | ﹤0.01% |
+14,198
| New | +$22K |
|
Similar funds
ACA
GI
VPIM
RA
RI
HRCM
WAM
HI
INTECH Investment Management's Q4 2024 Portfolio in Review
As of Q4 2024, INTECH Investment Management held 2,444 positions worth $10.3B, up 15% from $8.94B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
INTECH Investment Management deployed $1.28B of net new capital in Q4 2024, opening 431 new positions and adding to 1,575 existing holdings. Its largest new stake was Lam Research: 135,738 shares worth $9.8M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $109M trimmed.
- INTECH Investment Management's largest Q4 2024 buy was Lam Research: 135,738 shares worth $9.8M.
- INTECH Investment Management added most to Merck in Q4 2024, an estimated $48.2M increase.
- INTECH Investment Management's biggest Q4 2024 reduction was Apple, cutting an estimated $109M.
- INTECH Investment Management fully exited Vanguard Russell 2000 ETF in Q4 2024, selling an estimated $64.9M.
- INTECH Investment Management's ten largest holdings make up 26% of its $10.3B portfolio in Q4 2024.
- INTECH Investment Management opened 431 new positions and closed 67 in Q4 2024.
- INTECH Investment Management's portfolio value rose 15% quarter-over-quarter to $10.3B.
Based on INTECH Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.